Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Deloitte
Johnson and Johnson
Julphar
US Army
Harvard Business School

Generated: May 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 10,076,615

« Back to Dashboard

Summary for Patent: 10,076,615
Title:Nasal delivery
Abstract: A nasal delivery device for and method of delivering substance to a nasal cavity of a subject, the delivery device comprising: a nosepiece for fitting to a nostril of a subject, wherein the nosepiece comprises a tip element which includes a delivery aperture from which substance is in use delivered into the nasal cavity, and the tip element is at least in part tapered such as to be inclined to a longitudinal axis of the nosepiece, with the delivery aperture extending both laterally across the tip element and along a longitudinal extent of the tip element; a nozzle through which substance is in use delivered, preferably substantially axially to a longitudinal axis of the nosepiece, to the respective nasal cavity; and a delivery unit for delivering substance through the nozzle of the nosepiece.
Inventor(s): Djupesland; Per Gisle (Oslo, NO), Sheldrake; Colin David (Wiltshire, GB)
Assignee: OptiNose AS (Oslo, NO)
Application Number:14/618,273
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 10,076,615
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 10,076,615

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Avanir Pharms ONZETRA XSAIL sumatriptan succinate POWDER;INHALATION 206099-001 Jan 27, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY ➤ Sign Up
Avanir Pharms ONZETRA XSAIL sumatriptan succinate POWDER;INHALATION 206099-001 Jan 27, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY ➤ Sign Up
Avanir Pharms ONZETRA XSAIL sumatriptan succinate POWDER;INHALATION 206099-001 Jan 27, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE ➤ Sign Up
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 10,076,615

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0706863.8Apr 5, 2007

International Family Members for US Patent 10,076,615

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2136865 ➤ Sign Up
United Kingdom 0706863 ➤ Sign Up
United Kingdom 2448193 ➤ Sign Up
World Intellectual Property Organization (WIPO) 2008122791 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Covington
Farmers Insurance
Harvard Business School
Chinese Patent Office
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.